Tolterodine ER

ApprovedSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Tolterodine ER is one of 94 small molecule programs targeting Lower Urinary Tract Symptom. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Urinary Tract SymptomActive, not recruiting

CognitionActive, not recruiting

Overactive BladderActive, not recruiting

Lower Urinary Tract SymptomApproved

Active, not recruiting

CognitionApproved

Active, not recruiting

Overactive BladderApproved

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Cognition

#DrugCompanyPhaseTrials

Tolterodine ER

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Activella

Eli Lilly

Preclinical

2 3

Estrace

Novo Nordisk

Preclinical

2 4

Resotran

Takeda

Preclinical

1 5

Ozempic

Novo Nordisk

Preclinical

1 6

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 7

Marinol

Alnylam Pharmaceuticals

Preclinical

1 8

Veramyst

GSK

Preclinical

1 9

Florinef

Alnylam Pharmaceuticals

Preclinical

1 10

Galvus

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder7 trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Completed· Pfizer logo

Pfizer·Phase 3·NCT00611026·2,417 enrolled

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT01302938·18 enrolled

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01500382·4 enrolled

Show 4 more trials

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00137397·80 enrolled

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01314872·1,395 enrolled

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Completed· Astellas logo

Astellas·Phase 4·NCT02138747·376 enrolled

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Completed· Astellas logo

Astellas·Phase 3·NCT01043666·1,126 enrolled

Treatment1 trial

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT01741454·181 enrolled

Cognition1 trial

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00411437·220 enrolled

Lower Urinary Tract Symptom1 trial

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

Completed·SSiami, Paul F., M.D.·Phase 4·NCT00939120·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Tolterodine ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tolterodine ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tolterodine ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Tolterodine ER

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder7 trials

Treatment1 trial

Cognition1 trial

Lower Urinary Tract Symptom1 trial

References

Drug Info

Quick Facts

Related News